What is Kairos Pharma, Ltd. (KAPA) stock price today?

Kairos Pharma, Ltd. (KAPA) currently trades at $0.55 per share. The stock has a market capitalization of $12.83M and a P/E ratio of —x.

Is KAPA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kairos Pharma, Ltd. has a Smart Value Score of 21/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -2.27.

Is Kairos Pharma, Ltd. financially healthy?

Kairos Pharma, Ltd.'s Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -2.27 places it in the distress.

KAPA

Kairos Pharma, Ltd.

NYSE MKT: KAPA · HEALTHCARE · BIOTECHNOLOGY

$0.55

-6.44% today

Updated 2026-04-29

Market cap

$12.83M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.30

Dividend yield

—

52W range

$0 – $2

Volume

0.6M

Market cap

$12.83M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.30

Dividend yield

—

52W range

$0 – $2

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.3

Quality

C+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-2.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$8.33

+1409.06%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -2.27 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-1.92M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-1.05M	$-1.81M	$-2.60M	$-5.45M	$-1.36M
EPS	—	—	—	—	$-0.30
Free cash flow	$-353000.00	$81000.00	$-3.96M	$-3.44M	$-1.92M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KAPA	$12.83M	21	4.3	3.0	5.0	5.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Kairos Pharma, Ltd. trades at $0.55. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -2.27, it sits in the distress.

Frequently asked questions

What is Kairos Pharma, Ltd.'s stock price?

Kairos Pharma, Ltd. (KAPA) trades at $0.55.

Is Kairos Pharma, Ltd. overvalued?

Smart Value Score 21/100 (Grade F, Strong Sell).

What is the price target of Kairos Pharma, Ltd. (KAPA)?

The analyst target price is $8.33, representing +1409.1% upside from the current price of $0.55.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-2.27 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

Quick metrics

P/S ratio—

ROE-98.00%

Beta—

50D MA$0.60

200D MA$0.90

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KAPA vs LLY →KAPA vs JNJ →KAPA vs ABBV →Stock screener →